Nature

CD123 immunostaining patterns in systemic mastocytosis: differential expression in disease subgroups and potential prognostic value

CD123 is the α-subunit of the interleukin-3 receptor; it represents a potential therapeutic target in systemic mastocytosis (SM) given its absent expression on normal/reactive mast cells (MCs) and ...
ascopubs.org

Real-world clinical characteristics and outcomes of systemic mastocytosis (SM) patients (Pts) in the era of targeted treatments (Txs): A single-center cohort analysis.

Analyzing trends and disparities in polycythemia vera mortality in the U.S. from 1999 to 2020.
ascopubs.org

MARS: Mutation-Adjusted Risk Score for Advanced Systemic Mastocytosis

Positron Emission Tomography–Guided Treatment in Early-Stage Favorable Hodgkin Lymphoma: Final Results of the International, Randomized Phase III HD16 Trial by the German Hodgkin Study Group The study ...
PMLiVE

NICE recommends Blueprint Medicines’ Ayvakyt to treat rare blood disorder

The National Institute for Health and Care Excellence (NICE) has recommended Blueprint Medicines’ Ayvakyt (avapritinib) to treat patients with the rare blood disorder systemic mastocytosis (SM). The ...